史录文 - 北京大学

个人简介

教育背景美国伊利诺斯芝加哥大学医学教育管理硕士（1992）北京医科大学理学学士（1987）工作经历 2000.04-2019.12 北京大学药学院药事管理与临床药学系，教授，主任 2002.12-至今北京大学医药管理国际研究中心，主任，研究员 2005.09-2006.08 北京市卫生局局长助理（挂职） 2000.04-2005.11 北京大学医学部，副主任，党委委员 1997.03-2000.03 北京医科大学后勤与基建处，处长，后勤党委副书记 1992.03-1997.03 北京医科大学药学院，副院长，机关支部书记 1992.05-2000.03 北京医科大学药学院药事管理学教研室，主任临床药学教研室，副主任，副教授

研究领域

我国医药卫生事业发展与改革策略，医药政策与法律，医药产业发展策略，药学教学管理与改革，药事管理学和临床药学学科发展与教学实践体系，药物利用与医药经济学，用药行为学，药学服务及其评估体系等

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Zhang Y, Katharina Wagner A, Du H, Han T, Gupta S, Denburg AE, Frazier AL, Guan X, Shi L*. Childhood cancer drugs in China:An overview and comparison of regulatory approvals in China and the United States. Int J Cancer.2022 Feb 1;150(3):482-490. Fu M, Wushouer H, Hu L, Li N, Guan X, Shi L*, Ross-Degnan D. Outpatient prescribing pattern for acute bronchitis in primary healthcare settings in China. NPJ Prim Care Respir Med. 2021 May 10;31(1):24. Wei G, Wu M, Zhu H, Han S, Chen J, Zhai C, Shi L*. Off-Label Use of Antineoplastic Drugs to Treat Malignancies:Evidence From China Based on a Nationwide Medical Insurance Data Analysis. Front Pharmacol. 2021 Apr 8;12:616453. Wei G, Zhu H, Han S, Chen J, Shi L*. Impact of house price growth on mental health: Evidence from China.SSM Popul Health.2020 Nov 19;13:100696. Li XX, Cheng YC, Zhai SD, Yao P, Zhan SY, Shi L*W. Risk of Liver Injury Associated with Intravenous Lipid Emulsions:A Prescription Sequence Symmetry Analysis. Front Pharmacol. 2021 Mar 1;12:589091. Guan H, Sheng Y, Guo W, Han S, Shi L*: Response Letter to "Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China". Adv Ther 2020, 37(2):971-972. Guan X, Zhang Y, Wushouer H, Shi L*, Ross-Degnan D, Wagner AK: Differences in reimbursement listing of anticancer therapies in China: an observational study. BMJ Open 2020, 10(1):e031203-e031203. Guan X, Ni B, Zhang J, Man C, Cai Z, Meng W, Shi L*, Ross-Degnan D: The Impact of Physicians' Working Hours on Inappropriate Use of Outpatient Medicine in a Tertiary Hospital in China. Appl Health Econ Health Policy 2019:10.1007/s40258-40019-00544-w. Guan X, Wushouer H, Yang M, Han S,Shi L*, Ross-Degnan D, Wagner AK: Influence of government price regulation and deregulation on the price of antineoplastic medications in China: a controlled interrupted time series study. BMJ Open 2019, 9(11):e031658-e031658. Guan H, Liu G, Xie F, Sheng Y,Shi L*: Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer in China. Clin Ther 2019, 41(11):2308-2320.e2311.